Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02477020 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

A Phase 2 study of Schizophrenia, sponsored by Takeda.

Completed
Registry status
Phase 2
Development phase
164
Enrollment target
15
Study locations

NCT02477020 is a Phase 2 study of Schizophrenia that has completed, run by Takeda. The registered enrollment target is 164 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower). The trial reports 15 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02477020, a Phase 2 study of Schizophrenia, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 2
Development phase
164 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG TAK-063 20 mg

Study Locations (15)

California

  • - Culver City
  • - Lemon Grove
  • - Long Beach
  • - Pico Rivera

Texas

  • - Austin
  • - Dallas
  • - Houston

Florida

  • - Lauderhill
  • - Orlando

Alaska

  • - Springdale

Georgia

  • - Atlanta

Louisiana

  • - Lake Charles

Missouri

  • - St Louis

Nevada

  • - Las Vegas

Trial Details

FieldValue
Enrollment Target 164 participants
Start Date 2015-07-01
Est. Completion 2016-07-27
Phase Phase 2

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02477020

The ClinicalTrials.gov registry entry for NCT02477020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02477020 reports 15 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Florida.

Frequently Asked Questions

What is clinical trial NCT02477020 about?

NCT02477020 is a clinical study titled "A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia". The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.

What is the current status of trial NCT02477020?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2015-07-01. Estimated completion is 2016-07-27.

What conditions does trial NCT02477020 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT02477020?

The interventions under investigation include: Placebo (DRUG), TAK-063 20 mg (DRUG).

Who is sponsoring clinical trial NCT02477020?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02477020 being conducted?

This trial has 15 study locations across Alaska, California, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.